Grifols, S.A. (GRFS)
NASDAQ: GRFS · IEX Real-Time Price · USD
6.79
+0.36 (5.60%)
At close: May 1, 2024, 4:00 PM
6.73
-0.06 (-0.88%)
After-hours: May 1, 2024, 7:18 PM EDT
Grifols Revenue
In the year 2023, Grifols had annual revenue of $7.32B with 13.54% growth.
Revenue (ttm)
$7.32B
Revenue Growth
+13.54%
P/S Ratio
0.78
Revenue / Employee
$308,565
Employees
23,737
Market Cap
5.72B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.32B | 873.39M | 13.54% |
Dec 31, 2022 | 6.45B | 845.21M | 15.08% |
Dec 31, 2021 | 5.61B | -906.43M | -13.92% |
Dec 31, 2020 | 6.51B | 783.38M | 13.67% |
Dec 31, 2019 | 5.73B | 571.71M | 11.09% |
Dec 31, 2018 | 5.16B | -24.74M | -0.48% |
Dec 31, 2017 | 5.18B | 919.81M | 21.58% |
Dec 31, 2016 | 4.26B | -11.34M | -0.27% |
Dec 31, 2015 | 4.27B | 213.59M | 5.26% |
Dec 31, 2014 | 4.06B | 289.49M | 7.68% |
Dec 31, 2013 | 3.77B | 313.07M | 9.06% |
Dec 31, 2012 | 3.46B | 1.13B | 48.73% |
Dec 31, 2011 | 2.32B | 999.88M | 75.49% |
Dec 31, 2010 | 1.32B | 15.20M | 1.16% |
Dec 31, 2009 | 1.31B | 174.54M | 15.38% |
Dec 31, 2008 | 1.13B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Option Care Health | 4.43B |
Bausch + Lomb | 4.15B |
R1 RCM | 2.25B |
Halozyme Therapeutics | 829.25M |
Ionis Pharmaceuticals | 787.65M |
Apellis Pharmaceuticals | 396.59M |
Glaukos | 314.71M |
Blueprint Medicines | 249.38M |
GRFS News
- 12 days ago - Grifols 2023 Annual Report on Form 20-F filed with the SEC - PRNewsWire
- 13 days ago - Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - GlobeNewsWire
- 15 days ago - IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 17 days ago - Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters
- 22 days ago - Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake - Reuters
- 23 days ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 27 days ago - Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor - Reuters
- 4 weeks ago - Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening - GlobeNewsWire